KARACHI: The Searle Company Limited reported robust financial results for the third quarter and nine months ended March 31, 2026, with significant growth in revenue and profitability, while also announcing a strategic initiative to restructure its product portfolio across group companies.
According to the company’s financial statements approved by the Board of Directors on April 29, 2026, Searle recorded an unconsolidated quarterly profit after tax of Rs524.35 million, compared to Rs307.54 million in the corresponding period last year, reflecting a year-on-year increase of approximately 70%. Earnings per share (EPS) improved to Rs0.89 from Rs0.52.
For the nine-month period ended March 31, 2026, unconsolidated profit surged to Rs2.31 billion, more than eight times higher than Rs268.81 million reported in the same period last year. Revenue for the nine months climbed to Rs26.19 billion, up from Rs19.11 billion, supported by higher sales and improved operating performance.
On a consolidated basis, the pharmaceutical company posted a quarterly profit of Rs501.98 million, reversing a loss of Rs353.88 million recorded in the corresponding quarter of FY2025. Consolidated earnings for the nine-month period reached Rs2.31 billion, compared with a loss of Rs284.52 million a year earlier, demonstrating a strong turnaround in group performance. Consolidated revenue increased to Rs29.39 billion during the nine months, compared with Rs21.99 billion in the same period last year.
Despite the improved financial performance, the Board did not recommend any cash dividend, bonus shares, or right shares for shareholders for the quarter.
Alongside the financial results, Searle disclosed a significant strategic development. The Board has authorized management to evaluate the transfer of one or more products between its subsidiaries as part of a broader portfolio rationalization strategy aimed at strengthening future consolidated growth. The company has also been authorized to appoint advisors, valuators, and consultants to assess the feasibility of the proposed restructuring, finalize the transaction structure, and prepare the necessary documentation for the Board’s consideration.
The planned restructuring reflects Searle’s continued focus on optimizing its business operations and aligning its product portfolio to enhance long-term operational efficiency and shareholder value while building on its improved financial momentum.
